Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 23;40(31):3593–3602. doi: 10.1200/JCO.21.02278

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG A4. — Changes from baseline in EORTC QLQ-C30 Cognitive and Emotional Functioning scores with lorlatinib by (A and B) CNS adverse events; (C and D) cognitive effects; and (E and F) mood effects cluster terms (PRO population). The PRO population consisted of all randomly assigned patients who completed a baseline assessment and at least one postbaseline assessment. COGNITIVE EFFECTS were any events from HLGT Cognitive and attention disorders and disturbances, Deliria (including confusion) or Mental impairment disorders; MOOD EFFECTS were any events from HLGT Anxiety disorders and symptoms, Depressed mood disorders and disturbances, Manic and bipolar mood disorders and disturbances, Mood disorders and disturbances not elsewhere classified, or Personality disorders and disturbances in behavior. ^aBL was defined as the last assessment performed on or before the date of the first dose of study treatment. CNS effects defined as any event from the cognitive effects, mood effects, speech effects, or psychotic effects cluster terms. BL, baseline; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; HLGT, high-level group terms; PRO, patient-reported outcome.